Congress Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Congress Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$203K	Sell	409 -203	-33%	-$90K	﹤0.01%	371
2026 Q1	$273K	Sell	612 -325	-35%	-$152K	﹤0.01%	407
2025 Q4	$425K	Sell	937 -159,938	-99%	-$68.9M	﹤0.01%	349
2025 Q3	$63M	Sell	160,875 -27,129	-14%	-$11.3M	0.42%	91
2025 Q2	$83.7M	Buy	188,004 +428	+0.2%	+$197K	0.57%	65
2025 Q1	$90.9M	Buy	187,576 +40,427	+27%	+$18.8M	0.68%	54
2024 Q4	$59.3M	Sell	147,149 -41,431	-22%	-$19.2M	0.4%	95
2024 Q3	$87.7M	Buy	188,580 +6,919	+4%	+$3.32M	0.6%	76
2024 Q2	$85.1M	Buy	181,661 +180,286	+13,112%	+$78.3M	0.61%	75
2024 Q1	$575K	Hold	1,375	–	–	﹤0.01%	318
2023 Q4	$559K	Sell	1,375 -19	-1%	-$7.02K	﹤0.01%	337
2023 Q3	$485K	Sell	1,394 -125	-8%	-$43.7K	﹤0.01%	338
2023 Q2	$535K	Hold	1,519	–	–	﹤0.01%	328
2023 Q1	$479K	Sell	1,519 -62	-4%	-$18.6K	﹤0.01%	334
2022 Q4	$457K	Sell	1,581 -20	-1%	-$6.09K	﹤0.01%	342
2022 Q3	$464K	Sell	1,601 -17,578	-92%	-$5.06M	0.01%	329
2022 Q2	$5.4M	Buy	19,179 +17,028	+792%	+$4.56M	0.05%	211
2022 Q1	$561K	Sell	2,151 -1,302	-38%	-$309K	﹤0.01%	330
2021 Q4	$758K	Sell	3,453 -666	-16%	-$130K	0.01%	321
2021 Q3	$747K	Sell	4,119 -337,617	-99%	-$65.9M	0.01%	310
2021 Q2	$68.9M	Sell	341,736 -615	-0.2%	-$129K	0.58%	77
2021 Q1	$73.6M	Buy	342,351 +29,923	+10%	+$6.57M	0.66%	77
2020 Q4	$73.8M	Buy	312,428 +10,938	+4%	+$2.51M	0.7%	75
2020 Q3	$82M	Buy	301,490 +2,844	+1%	+$785K	0.89%	62
2020 Q2	$86.7M	Sell	298,646 -5,099	-2%	-$1.38M	1.03%	44
2020 Q1	$72.3M	Sell	303,745 -3,672	-1%	-$842K	1.1%	42
2019 Q4	$67.3M	Sell	307,417 -1,439	-0.5%	-$291K	0.82%	62
2019 Q3	$52.3M	Buy	308,856 +5,779	+2%	+$1.02M	0.67%	76
2019 Q2	$55.6M	Buy	303,077 +22,210	+8%	+$3.88M	0.71%	74
2019 Q1	$51.7M	Buy	280,867 +2,319	+0.8%	+$428K	0.68%	74
2018 Q4	$46.2M	Buy	278,548 +17,172	+7%	+$2.98M	0.69%	72
2018 Q3	$50.4M	Buy	261,376 +8,644	+3%	+$1.54M	0.65%	73
2018 Q2	$43M	Buy	+252,732	New	+$39.2M	0.59%	79
2013 Q3	–	Sell	-53,222	Closed	-$4.26M	–	231
2013 Q2	$4.26M	Buy	+53,222	New	+$3.92M	0.13%	111

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

MLL

Moody Lynn & Lieberson Boston, Massachusetts $1.9B AUM 27.82% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Congress Asset Management's VRTX Position: Q2 2026 in Review

Congress Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 33% in Q2 2026, selling an estimated $90K and leaving 409 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #371.

Congress Asset Management first reported a position in VRTX in Q2 2013 and has held it in 34 quarters since. The position peaked at $90.9M in Q1 2025. 296 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Congress Asset Management held 409 shares of Vertex Pharmaceuticals worth $203K as of Q2 2026.
Congress Asset Management sold 203 Vertex Pharmaceuticals shares in Q2 2026, an estimated $90K.
Vertex Pharmaceuticals made up ﹤0.01% of Congress Asset Management's portfolio in Q2 2026, its #371 holding.
Congress Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 34 quarters since.
Congress Asset Management's Vertex Pharmaceuticals position peaked at $90.9M in Q1 2025.
296 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Congress Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.